Search company, investor...


Founded Year



Other Investors | Alive

About tulex

Headquarters Location

Fleher Str. 4



Missing: tulex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: tulex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest tulex News

Eton acquires Tulex's pediatric rare disease drug ET-600

Mar 15, 2023

Delmaine Donson Terms of the transaction were not disclosed, currently. ET-600 is being developed to treat an endocrinology condition that is estimated to impact less than 5K children in the U.S., according to the company. "As a rare disease product that builds on our established presence in pediatric endocrinology, ET-600 is a perfect strategic fit for our portfolio," said Eton CEO Sean Brynjelsen. Eton expects to file a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the therapy in Q2 2024, which could allow for an approval and launch of the product in early 2025. Recommended For You

tulex Frequently Asked Questions (FAQ)

  • When was tulex founded?

    tulex was founded in 2005.

  • What is tulex's latest funding round?

    tulex's latest funding round is Other Investors.

  • Who are the investors of tulex?

    Investors of tulex include High-Tech Grunderfonds and Sirius Venture Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.